Tilray, Inc. (TLRY) Analysts See $-0.14 EPS

November 10, 2018 - By James Guidry

Analysts expect Tilray, Inc. (NASDAQ:TLRY) to report $-0.14 EPS on November, 27.After having $-0.17 EPS previously, Tilray, Inc.’s analysts see -17.65 % EPS growth. The stock decreased 8.18% or $9.71 during the last trading session, reaching $108.99. About 3.00 million shares traded. Tilray, Inc. (NASDAQ:TLRY) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company has market cap of $10.15 billion. The firm offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. It currently has negative earnings.

More notable recent Tilray, Inc. (NASDAQ:TLRY) news were published by: Fool.com which released: “Here’s What Could Give Marijuana Stocks Their Next Move Higher” on November 10, 2018, also Fool.com with their article: “Why Tilray Crushed It Today” published on November 07, 2018, Fool.com published: “Better Marijuana Stock: Tilray vs. Origin House” on November 04, 2018. More interesting news about Tilray, Inc. (NASDAQ:TLRY) were released by: Fool.com and their article: “Better Marijuana Stock: Tilray vs. CannTrust Holdings” published on October 28, 2018 as well as Seekingalpha.com‘s news article titled: “High On Tilray: Will Investors Suffer Withdrawal?” with publication date: November 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.